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Behavioral/Cognitive
Functional Upregulation of 4* Nicotinic Acetylcholine
Receptors in VTA GABAergic Neurons Increases Sensitivity
to Nicotine Reward
Jennifer Ngolab,1 Liwang Liu,1 Rubing Zhao-Shea,1 Guangping Gao,2,3 Paul D. Gardner,1 and Andrew R. Tapper1
1Brudnick Neuropsychiatric Research Institute, Department of Psychiatry and 2Gene Therapy Center, 3Department of Microbiology and Physiological
Systems, University of Massachusetts Medical School, Worcester, Massachusetts 01604
Chronic nicotine exposure increases sensitivity to nicotine reward during a withdrawal period, whichmay facilitate relapse in abstinent
smokers, yet the molecular neuroadaptation(s) that contribute to this phenomenon are unknown. Interestingly, chronic nicotine use
induces functional upregulation of nicotinic acetylcholine receptors (nAChRs) in the mesocorticolimbic reward pathway potentially
linkingupregulation to increaseddrug sensitivity. In theventral tegmental area (VTA), functionalupregulationofnAChRscontaining the
4 subunit (4* nAChRs) is restricted toGABAergic neurons. To test the hypothesis that increased functional expression of4* nAChRs
in these neurons modulates nicotine reward behaviors, we engineered a Cre recombinase-dependent gene expression system to selec-
tively express 4 nAChR subunits harboring a “gain-of-function” mutation [a leucine mutated to a serine residue at the 9 position
(Leu9Ser)] in VTA GABAergic neurons of adult mice. In mice expressing Leu9Ser 4 nAChR subunits in VTA GABAergic neurons
(Gad2VTA:Leu9Sermice), subreward thresholddosesofnicotinewere sufficient to selectively activateVTAGABAergicneurons andelicit
acute hypolocomotion, with subsequent nicotine exposures eliciting tolerance to this effect, compared to control animals. In the condi-
tioned place preference procedure, nicotine was sufficient to condition a significant place preference in Gad2VTA:Leu9Ser mice at low
nicotine doses that failed to condition control animals. Together, these data indicate that functional upregulation of4* nAChRs inVTA
GABAergic neurons confers increased sensitivity to nicotine reward and points to nAChR subtypes specifically expressed in GABAergic
VTA neurons as molecular targets for smoking cessation therapeutics.
Key words: GABA; nicotine; nicotinic receptor; reward
Introduction
Chronic exposure to tobacco smoke accounts for 5 million
deaths per year, making health complications from smoking the
primary cause of preventable mortality in the world (Harris and
Anthenelli, 2005). Nicotine, the addictive component of tobacco,
binds to and activates neuronal nicotinic acetylcholine receptors
(nAChRs), ligand-gated cation channels that are normally acti-
vated by the endogenous neurotransmitter, acetylcholine (ACh).
Nicotine initiates dependence by activating neurons within the
ventral tegmental area (VTA) of the mesocorticolimbic reward
circuitry, ultimately driving the release of dopamine (DA) within
the nucleus accumbens (NAc), a phenomenon widely associated
with the rewarding or reinforcing value of nicotine (De Biasi and
Dani, 2011). A large variety of nAChR subunit genes are ex-
pressed in bothVTADAergic projection neurons andGABAergic
neurons (Klink et al., 2001; Wooltorton et al., 2003).
Neuronal nAChRs are pentameric receptors consisting of ho-
mologous or heterologous combinations of subunits. Twelve
genes encoding 12 individual nAChR subunits have been identi-
fied, accounting for a vast array of nAChR subtypes each with
distinct pharmacological and biophysical properties. A great deal
of effort has focused on identifying nAChR subtype expression
within the VTA to determinewhich subtypes, when activated, are
necessary and sufficient for nicotine reinforcement and/or re-
ward (Picciotto et al., 1998; Tapper et al., 2004; Maskos et al.,
2005; Pons et al., 2008). From these studies, a general consensus is
that expression of nAChRs containing 4 and 2 subunits in the
VTA are both necessary and sufficient for nicotine reinforcement
with at least some contribution of the 6 subunit (Pons et al.,
2008; Brunzell et al., 2010; Gotti et al., 2010).However,4 and2
subunits are expressed in both VTA DAergic neurons and
GABAergic neurons (Klink et al., 2001; Wooltorton et al., 2003).
Although nicotine can directly activate VTA DAergic neurons,
previous studies suggest that activation of GABAergic neurons
may also modulate DAergic neuron activity and is required for
nicotine reinforcement (Tolu et al., 2012).
Unlike other drugs of abuse, chronic use of nicotine leads to
increased expression or “upregulation” of 42* nAChRs (the
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asterisk denotes that nAChR subunits in addition to 4 and 2
may be assembled in the nAChR complex) in the mesocortico-
limbic pathways in addition to other brain regions. Although
upregulation of nAChRs is a hallmark of chronic nicotine expo-
sure, the behavioral consequence of this phenomenon and how it
relates to nicotine dependence is unknown (Wonnacott, 1990).
Interestingly, functional upregulation of 4* nAChRs in the me-
solimbic pathway appears to be restricted to midbrain GABAer-
gic neurons including those of theVTA (Nashmi et al., 2007; Xiao
et al., 2009). In addition, the rewarding properties of nicotine
have been shown to increase in chronic nicotine-exposed mice,
perhaps linking upregulation and increased functional 4*
nAChR expression in VTA GABAergic neurons with reward be-
havior (Hilario et al., 2012).We sought to test the hypothesis that
increased functional expression of 4* nAChRs selectively in
VTA GABAergic neurons will increase sensitivity to nicotine
reward.
Materials andMethods
Mice. C57BL/6J and glutamate decarboxylase 2 (Gad2)-Cre (strain
B6N.Cg-Gad2tmz(cre)Zhj/J ) male mice on a C57BL/6J background were
used in this study (The Jackson Laboratory; Taniguchi et al., 2011). Adult
(8 to 10 weeks old) Gad2-Cre mice were injected with viral particles and
used for behavioral experiments 4–6 weeks after infection. All mice were
kept on a 12 h light/dark cycle, with lights on at 7:00 A.M. and off at 7:00
P.M. All mice were given food and water ad libitum. All procedures were
performed in compliance with the Institutional Animal Care and Use
Committee of the University of Massachusetts Medical School.
Drugs. For acute treatments, nicotine hydrogen tartrate, mecamyl-
amine hydrocholoride (Sigma-Aldrich), and dihydro--erythroidine
hydrobromide (DHE; Tocris Bioscience) were dissolved in sterile 0.9%
PBS (Hospira). Nicotine was titrated to physiological pH (7.4) before
being administered to mice. Vials containing nicotine solutions were
wrapped in aluminum foil to prevent degradation by light exposure. For
chronic exposure studies, nicotine dihydrate ditartrate (200 g/ml; Ac-
ros Organics) and L-tartaric acid (300 g/ml; Sigma-Aldrich) were dis-
solved inwater. Saccharin sodium (3mg/ml; Fisher Scientific) was added
to both solutions to increase palatability. Doses for nicotine, mecamyl-
amine, and DHE were calculated as free base. All injections were ad-
ministered subcutaneously.
Viral plasmid engineering. The mouse 4-yellow fluorescent protein
(YFP) nAChR subunit cDNA was obtained from Addgene (plasmid
15245) and has been described previously (Nashmi et al. 2003). Using the
QuikChange site-directed mutagenesis kit (Agilent Technologies), PCR
mutagenesis was done to convert the 9 leucine of theM2 pore domain to
a serine (changing the codon fromCTT to TCT). The resulting construct
contained 4-YFP cDNA with the leucine to serine mutation (Leu9Ser
4-YFP). The Leu9Ser 4-YFP cDNA was subcloned into the AAV ex-
pression vector pAAV-EF-1a-DIO-WPRE-pA (Tsai et al., 2009).
Chronic nicotine exposure. Animals were restricted to drinking either
control (tartaric acid, 300 g/ml and 3 mg/ml saccharin) or nicotine-
treated (200 g/ml and 3 mg/ml saccharin) water through a 250 ml
opaque water bottle placed in the home cage for 6–8 weeks. To induce
withdrawal, the nicotine bottle was replaced with a water bottle (Zhao-
Shea et al., 2013).
Viral-mediated gene delivery.Both the pAAV-EF-1a-Leu9Ser-4-YFP
(Leu9Ser 4-YFP) and pAAV-EF-1a-DIO-hChR2(H134R)-EYFP-
WPRE-pA (control) constructs were packaged into AAV2 viral particles
by the University of Massachusetts Medical School Viral Vector Core.
Viral titers were 1012 viral particles/l with 1 l of viral supernatant
bilaterally injected into the VTA. Gad2-Cre animals were anesthetized
with ketamine/xylazine (0.1 ml/10 g body weight, 10 mg/ml ketamine, 1
mg/ml xylazine). To prepare the surgical area, fur was shaved, and skin
was disinfected with 10% povidone iodine. The VTA was located with
a stereotaxic frame (Stoelting) using the following coordinates from
bregma (in mm): 3.3 AP, 0.3 ML, 4.0 DV. Viral particles were
infused into the brain using an injection syringe (Hamilton) attached to
a syringe pump (Quintessential Stereotaxic Injector, Stoelting) at a rate
of 0.25l/min. The injection needle was left in place for 10min after each
injection and then slowly retracted. Mice were given 5% glucose and 15
mg/kg ketaprofen after fully regaining consciousness. Mice were given 4
weeks for recovery and to allow for expression of the viral particles before
each experiment.
Immunofluorescence. For c-Fos immunolabeling, animals received
subcutaneous saline injections 3 d before each experiment to reduce
possible effects of stress and/or handling on neuronal activity. To assess
c-Fos expression, Gad2-Cre male mice infected with either control or
Leu9Ser 4-YFP were injected either with saline or 0.09mg/kg nicotine.
Ninetyminutes after drug administration, brains were harvested for slice
preparation. Animals were anesthetized with 200 mg/kg sodium pento-
barbital (interperitoneal injection) and transcardially infused with 10ml
of chilled 0.1 M PBS following with chilled 4% (w/v) paraformaldehyde
dissolved in 0.1 M PBS. The brains were harvested and placed in cold 4%
paraformaldehyde for 2 h before submerging in 30% sucrose. Brainswere
then sectioned into 30 m slices using a microtome (Leica) and immu-
nolabeled via free-floating sections. Slices were washed in PBS for 5 min,
permeabilized in 0.2% (v/v) Triton X-100 (Sigma-Aldrich) for 5 min,
and blocked with 2% bovine serum albumin (BSA; Fisher Scientific) for
30min before incubation with primary antibody in 2% BSA overnight at
4 °C. Primary antibodies used were as follows: mouse anti-TH MAB318
(1:1000; lot number 2499557,Millipore), rabbit anti-Gad1/2 (1:2000; lot
number 122M4761, Sigma-Aldrich), rabbit anti-c-Fos (1:1000; lot num-
ber F2510, Santa Cruz Biotechnology), rabbit anti-GFP (1:4000; lot
number GR158277-1, Abcam), mouse anti-calbindin (1:3000; lot num-
ber 052M4833, Sigma-Aldrich), rabbit anti-calretinin (1:1000; lot num-
ber AB5054, Millipore), rabbit anti-parvalbumin (1:1000; lot number
ab11427, Abcam), and goat anti-somatostatin (1:100; lot number sc-789,
Santa Cruz Biotechnology). Secondary antibodies were Alexa Fluor 405
(lot number 1126599), 488 (lot number 1608521), and 594 (lot numbers
1431805, 1003216, and 1602780; 1:1000; Invitrogen). AnAxioCamMRm
camera (Carl Zeiss) attached to a Zeiss Axiovert inverted fluorescent
microscope equipped with Zeiss filter sets 38HE, 49, and 20 was used to
acquire fluorescent images. Zeiss objectives A-plan 10, EC-Plan-
NEOFLUAR 20, and Plan-APOCHROMAT 63 were used to view
and capture images. Images were processed using Axiovision version
4.8.2. For quantification and colocalization analysis, images were decon-
voluted and segmented using the segmentation and quantification of
subcellular shapes (Squassh) software plugin through ImageJ. At least 10
slices/mouse brain that spanned the entire VTAwere analyzed. The VTA
was located usingTH staining andmorphology of nearby brain regions as
described previously (Zhao-Shea et al., 2011). Areas of interest for each
slice were identified through TH fluorescence and measured in ImageJ
using the “Analyze Particles” option to account for differences between
slices.
Electrophysiological recordings.Mice were deeply anesthetized with so-
dium pentobarbital (200 mg/kg, i.p.) and then decapitated. Slices were
prepared as described previously (Zhao-Shea et al., 2011). Briefly, brains
were quickly removed and placed in an oxygenated ice-cold high sucrose
artificial CSF (SACSF) containing kynurenic acid (1 mM; Sigma-
Aldrich). Brain slices (180–200 m) were cut using a Leica VT1200
vibratome. The brain slices were incubated in oxygenated Earl’s balanced
salt solution supplemented with glutathione (1.5 mg/ml; Sigma), N--
nitro-L-argininemethyl ester hydrochloride (2.2mg/ml; Sigma), pyruvic
acid (11 mg/ml; Sigma), and kynurenic acid (1 mM) for 45 min at 34°C.
Slices were transferred into oxygenated ACSF at room temperature for
recording. SACSF solution contained the following (inmM): 250 sucrose,
2.5 KCl, 1.2 NaH2PO4  H2O, 1.2 MgCl2  6 H2O, 2.4 CaCl2  2 H2O, 26
NaHCO3, 11 D-glucose. Single slices were transferred into a recording
chamber continually superfused with oxygenated ACSF. The junction
potential between the patch pipette and bath ACSF was nullified just
before obtaining a seal on the neuronalmembrane. Action potentials and
currents were recorded at 32°C using the whole-cell configuration of a
Multiclamp 700B patch-clamp amplifier (Molecular Devices). Action
potentials were obtained using a gap-free acquisitionmode andClampex
software (Molecular Devices). Ih currents were elicited every 5 s by step-
ping from60mV to a test potential of120mV for 1 s using Clampex.
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Input resistances were calculated using steady state currents elicited by 5
mV hyperpolarizing pulses. Signals were filtered at 1 kHz using the am-
plifier’s four-pole, low-pass Bessel filter, digitized at 10 kHzwith anAxon
Digidata 1440A interface and stored on a personal computer. Potential
VTA GABAergic neurons were selected for recording based on fluores-
cent signal and further verified by action potential frequency (10–20
Hz) and lack of Ih expression. At the end of recording, the neuronal
cytoplasmwas aspirated into the recording pipette, and the contentswere
expelled into a microcentrifuge tube containing 75% ice-cold ethanol
and stored at 20°C for at least 2 h before single-cell RT-PCR experi-
ments to verify expression of GAD1 and GAD2. ACh chloride (Sigma)
was dissolved in ACSF. Whole-cell ACh responses were recorded in the
presence of TTX (0.5 M), atropine (1 M), bicuculline (20 M), and
CNQX (10 M). Drugs were applied to slices by gravity superfusion.
Nicotine tolerance. Mice received subcutaneous saline injections 3 d
before testing to habituate to handling. Locomotor activity was recorded
as beam breaks using the Photobeam Activity System (PAS; San Diego
Instruments). To determine baseline activity, mice were injected with
saline and immediately placed into a novel cage inside the PAS locomotor
chamber. Activitywas quantified for 15min beforemicewere returned to
their home cage. On the second day, mice received a subcutaneous injec-
tion of nicotine andwere immediately placed into a novel cage within the
locomotor activity chamber. Activity was measured for 15 min. Mice
were subsequently injected with nicotine each day for 6 more days, with
locomotor activity recorded on the fourth and seventh days of nicotine
challenge.
Conditioned place preference.A three-chamber conditioned place pref-
erence (CPP) apparatus (Med Associates) was used to measure nicotine
reward. Briefly, at least 3 d before testing,mice were habituated to the test
room and handling by picking them up once a day by the scruff of the
neck. The testing protocol comprised three phases. In the pretraining
phase, mice were placed into the CPP apparatus and allowed to freely
explore all three chambers for 15 min. Time spent in each chamber was
quantified using MEDPC IV software (Med Associates). The training
phase lasted 4 d, where each day mice were twice confined to a chamber
for 30min. In themorning session, eachmousewas given a subcutaneous
injection of sterile saline andplaced in the chamber assigned as the saline-
paired chamber. Five hours later, each mouse was given a subcutaneous
injection of drug (i.e., nicotine) and placed in the opposite, drug-paired
chamber. The training phase was counterbalanced for each group in that
approximately half of the animals received nicotine paired with the white
chamber, whereas the other half received nicotine paired with the black
chamber. Drug was paired with the least preferred chamber. Mice that
spent70% of pretraining in any one chamber were not included in the
analysis. The post-training phase was identical to the pretraining phase.
Difference scores were measured by calculating the difference between
the time spent in a chamber during the post-training phase and during
the pretraining phase. For CPP experiments testing nicotine reward in
control and Leu9Ser4-YFP-infectedmice (see Fig. 3, Table 1), the CPP
procedurewas initiated 4–6weeks after infection.Mice received saline in
both chambers, 0.09 mg/kg nicotine, or 0.5 mg/kg nicotine (n  8–10
mice/group) during training. Additional groups of control and Leu9Ser
4-YFP-infected mice were tested for CPP to 1 mg/kg mecamylamine
(n  8–10 mice/group) or 0.5 or 2.0 mg/kg DHE (n  6–8 mice/
group) as described in Figure 4, A and B, and Table 1. For this set of
experiments, CPP was performed exactly as described above except in-
stead of nicotine during training,mice receivedmecamylamine orDHE
at the indicated dose. For CPP in nicotine-dependent mice (see Fig. 3C,
inset; Table 1), mice were exposed to nicotine in their drinking water for
8 weeks. Water bottles were swapped for untreated drinking water after
the completion of the CPP pretraining phase, and CPP was performed as
above using 0.5 mg/kg nicotine during training (n 11). An additional
group of control nicotine-naive animals were also tested in the CPP
procedure using 0.5 mg/kg nicotine (n 11).
Statistics. Normality of data was tested before analysis. Locomotor
activity data were analyzed using repeated measures one-way ANOVA.
CPP data were analyzed using two-way ANOVA with drug dose and
paired chamber as main factors, followed by Bonferroni’s post hoc anal-
ysis as indicated. c-Fos data were analyzed using two-way ANOVA with
virus and drug treatment or neuron subtype as main factors as indicated.
Fold-changedifferences in inward currentwere analyzedusing a two-tailed t
test. Data were analyzed using GraphPad Prism (GraphPad Software).
Results
Expression of gain-of-function 4 nicotinic receptor subunits
in VTA GABAergic neurons
To understand how increased functional expression of 4*
nAChRs in VTA GABAergic neurons affects behavior, we devel-
oped a viral-mediated gene delivery system to express 4* nico-
Table 1. Total time spent (in seconds) in drug- and saline-paired chambers of the CPP assay before (Pre) and after (Post) training
Sal (Pre, s) Sal (Post, s) Drug (Pre, s) Drug (Post, s)
Virus (Nic, mg/kg)
Ctrl (Sal) 379.7 20.86 315.7 48.44 280.2 18.88 335.5 45.96
Ctrl (0.09) 339 9.444 309.3 47.33 271.1 14.35 249.5 45.42
Ctrl (0.5) 334.9 32.69 341.1 21.41 284.9 17.82 299.3 24.08
Leu9Ser (Sal) 365.6 25.91 315.6 53.89 261.7 21.01 239.0-34.97
Leu9Ser (0.09) 347.6 21.93 205.9 27.43 257.1 17.7 437.9 37.28**,ˆ
Leu9Ser (0.5) 303.3 24.92 240.4 18.14 293 13.92 319.2 37.3
Leu9Ser (0.5, chronic nicotine) 382 10.11 294.1 19.78 306.8 16.57 376.1 19.33*,ˆ
Virus (Mec, mg/kg)
Ctrl (1.0) 409.2 28.42 352.5 40.04 282.3 29.93 317.6 43.69
Leu9Ser (1.0) 386.1 25.30 300.1 36.56 288.2 23.48 354.0 35.28
Virus (DHE, mg/kg)
Ctrl (0.5) 363.8 31.05 342.9 24.21 311.7 30.39 315.1 22.15
Ctrl (2.0) 447.6 31.12 332.2 38.96 226.3 32.76 285.9 44.42
Leu9Ser (0.5) 396.1 23.09 287.7 41.97 244 22.59 348.2 41.85
Leu9Ser (2.0) 383.1 16.36 352 55.83 309.4 12.95 309.6 55.02
Treatment/drug
Control/nicotine 367 20.3 328.5 23.48 268.8 18.67 263.7 26.09
Chronic nicotine/nicotine 400.2 29.79 263.2 23.39 261.1 15.01 379.6 26.02*,#
Ctrl, Control; Nic, nicotine; Sal, saline; Mec, mecamylamine.
*p	 0.05; **p	 0.01 
post-training compared to pretraining, two-way ANOVA with repeated measures (training and nicotine/saline treatment) and Bonferroni’s post hoc test.
#p	 0.01 
time spent in the nicotine-paired chamber after training for nicotine-dependent animals compared to time spent in the nicotine-paired chamber for nicotine-naïve animals; two-way ANOVAwith repeatedmeasures (Pre/Post
time spent in the Nic-paired chamber) and Bonferroni’s post hoc test.
ˆp	 0.001 
time spent in the nicotine-paired chamber after training compared to time spent in the control nicotine-paired chamber, i.e., group that received saline in the “drug-paired” chamber; two-way ANOVAwith repeatedmeasures
(Pre/Post time spent in the Nic-paired chamber) and Bonferroni’s post hoc test.
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tinic receptor subunits with a gain-of-functionmutation in select
neuronal populations allowing for selective activation of neurons
expressing this subunit with low doses of nicotine that minimally
activate non-4* nAChRs. We engineered an AAV plasmid con-
struct containing cDNA encoding the 4 nAChR subunit with a
single point mutation, a leucine mutated to serine, at the 9 resi-
due of the pore-forming, M2 domain (Leu9Ser; Fig. 1A), which
renders nAChRs that incorporate this subunit significantly more
sensitive to nicotine (Labarca et al., 2001). To visualize subunit
expression, a YFP tag was included in the M3–M4 intracellular
loop, where it does not interfere with receptor assembly or func-
tion (Leu9Ser 4-YFP; Nashmi et al., 2003; Nashmi et al., 2007).
The cDNA encoding Leu9Ser 4-YFP was positioned within the
AAV expression vector in the antisense orientation and flanked
by two pairs of distinct Lox sites (Fig. 1A). These Lox sites regu-
late Leu9Ser 4-YFP expression by directing recombination of
the cDNA cassette to the sense orientation in the presence of Cre
recombinase (Fig. 1A) (Tsai et al., 2009).
The expression vector was packaged into AAV2, a serotype
that will infect a brain region locally, and viral particles were
injected into the VTA of Gad2-Cre mice (Gad2VTA:Leu9Ser) for
expression of Leu9Ser4-YFP subunits selectively inGABAergic
neurons. To verify subunit expression in GABAegic neurons,
Gad2VTA:Leu9Ser midbrain slices were immunolabeled with ei-
ther an anti-TH or Gad1/2 antibody. VTA of infected mice ex-
hibited robust expression of Leu9Ser 4-YFP subunits, as
indicated by strong YFP fluorescent signal selectively in non-
DAergic neurons (Fig. 1B). To determine functional expression
of Leu9Ser4-YFP subunits inGABAergic VTAneurons, patch-
clamp recordings were made in Gad2VTA:Leu9Ser and control
midbrain slices. Control Gad2-Cre animals were infected with
AAV2 particles containing channelrhodopsin within the same
vector so that GABAergic neurons from control mice would ex-
press a non-nAChR membrane protein insensitive to nicotinic
agonists. The electrophysiological characteristics of infected neu-
rons, as identified by YFP fluorescent signal, were analyzed to
Figure1. Viral-mediatedgenedelivery of gain-of-function4nAChR subunits in VTAGABAergic neurons.A, Depiction of the Leu9Ser4-YFP subunit cDNAviral plasmid. Cre-recombinase flips
the Leu9Ser4-YFP subunit cDNA in the sense orientation. The viral particles containing this plasmid were intracranially injected into the VTA of Gad2-Cre mice for selective expression in VTA
GABAergic neurons.B, Top, Expressionof Leu9Ser4-YFP subunits innon-THneuronsofGad2-Cremice. Brain slices from infectedmicewere immunolabeled for TH to identifyDAergic neurons (red,
top, left). YFP fluorescence was detected, indicating Leu9Ser4-YFP subunit expression (green, top, middle). Merged signals revealed little colocalization of Leu9Ser4-YFP subunit expression
with DAergic neurons (top, right). Photomicrographs (bottom) of a representative VTA midbrain section from Gad2-Cre mice expressing Leu9Ser4-YFP subunits show neurons immunolabeled
for Gad (left) that also express Leu9Ser 4-YFP subunits (middle). The merged photomicrograph (right) shows colocalization of Gad and YFP signals. C, Cell-attached (top) and whole-cell
voltage-clamp (bottom) recordings fromaputativeVTAGABAergic neuron fromaGad2-Cremousemidbrain slice. GABAergic neurons typically haveahigh frequencyof firing (8–20Hz, top) and lack
of a hyperpolarizing activated current, Ih (bottom).D, At the end of each recording, single-neuron RT-PCRwas performed to verify Gad expression in a GABAergic neuron (left lanes) or TH expression
in aDAergic neuron (right lanes).E, Top,Whole-cell voltage-clamp recordings fromacontrol VTAGABAergic neuron inaGad2-Cremidbrain slice (left) andanLeu9Ser4-YFP-expressingGABAergic
neuron in aGad2-Cremidbrain slice (right). AChwasbath applied for 3minas indicatedby thebar above each trace. Average inward current fromcontrol infected (n5) and Leu9Ser4-YFP (n
8) infected VTA GABAergic neurons. **p	 0.01 (two-tailed t test). Error bars indicate SEM.
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confirm incorporation of the Leu9Ser 4-YFP subunit into an
nAChR. Leu9Ser 4-YFP-infected neurons exhibited fast-
spiking spontaneous action potentials and lacked an Ih current,
both characteristics of VTA GABAergic neurons (Fig. 1C; John-
son and North, 1992). Single-cell RT-PCR from the cytoplasm of
recorded neurons confirmed Gad1 and Gad2 expression in YFP-
positive neurons (Fig. 1D). To test for functional expression of
the Leu9Ser 4-YFP subunit, whole-cell current responses to
bath application of 1 mM ACh were recorded in infected Gad2-
Cre midbrain slices. ACh elicited robust inward currents in
Leu9Ser 4-YFP subunit-expressing VTA GABAergic neurons
that were significantly larger compared to responses from neu-
rons recorded from control slices (Fig. 1E). Together, these data
suggest that Gad2VTA:Leu9Ser mice express the Leu9Ser 4-
YFP subunit inGABAergic neurons, and the subunit coassembles
with endogenous subunits to form gain-of-function nAChRs.
Selective activation of VTA GABAergic neurons in
Gad2VTA:Leu9Ser mice
To test the hypothesis that a low dose of nicotine selectively in-
creased activation of VTA neurons in nicotine-naive Gad2VTA:
Leu9Ser mice compared to control animals, we challenged each
group with saline or an acute dose of 0.09 mg/kg nicotine and
immunolabeled VTA slices for c-Fos expression, an immediate
early gene that is a marker for neuron activation (Cole et al.,
1989). Two-way ANOVA indicated a significant main effect of
virus expression (F(1,22)  29.96, p 	 0.001) and nicotine treat-
ment (F(1,22) 31.62, p	 0.001), and a significant virus expres-
sion by nicotine treatment interaction (F(1,22) 22.23, p	 0.001;
Fig. 2A). Post hoc analysis indicated that there was a statistically
significant increase of c-Fos-immunopositive VTAneurons from
Gad2VTA:Leu9Sermice receiving 0.09mg/kg nicotine compared
to Gad2VTA:Leu9Ser mice receiving saline injection (p 	
0.0001). In addition, the number of c-Fos-immunopositive VTA
neurons in Gad2VTA:Leu9Ser mice was also significantly greater
than the number of c-Fos-immunopositive VTA neurons in
nicotine-treated control animals. In control mice, 0.09 mg/kg
nicotine did not significantly increase the number of c-Fos-
immunopositive VTAneurons compared to saline. To determine
whether nicotine-activated neurons were predominantly non-
DAergic, we challenged control andGad2VTA:Leu9Sermicewith
0.09 mg/kg nicotine and double immunolabeled for c-Fos and
TH (Fig. 2B,C). Two-way ANOVA revealed a significant main
effect of virus expression (F(1,22)  5.3, p 	 0.05) and neuron
subpopulation (F(1,22)  10.0, p 	 0.01), and a virus expression
by nicotine treatment interaction (F(1,22) 4.73, p	 0.05). Post
hoc analysis indicated that the number of TH-immunonegative,
c-Fos-immunopositive neurons inGad2VTA:Leu9Ser was signif-
icantly larger than TH-immunopositive, c-Fos-immunopositive
neurons after nicotine challenge (p	 0.01). The number of TH-
immunonegative, c-Fos-immunopositive neurons in Gad2VTA:
Leu9Ser was also larger than the number of TH-
immunonegative, c-Fos-immunopositive neurons in control
mice after nicotine challenge (p 	 0.05). The number of TH-
immunopositive, c-Fos-immunopositive neurons in Gad2VTA:
Leu9Ser mice after nicotine challenge was small and not
significantly different from control mice. In addition, YFP signal
could be detected in c-Fos-immunopositive neurons in
Gad2VTA:Leu9Ser mice, but not in control mice (Fig. 2B). To-
gether, these data indicate that 0.09 mg/kg nicotine selectively
activates non-DAergic (i.e., GABAergic) neurons in Gad2VTA:
Leu9Ser mice.
Nicotine activation of 4* nicotinic receptors in VTA
GABAergic neurons: locomotor effects
To test the hypothesis that functional upregulation of nAChRs in
GABAergic neurons may be involved in nicotine tolerance
(Nashmi et al., 2007), we measured nicotine-induced locomotor
activity in response to single daily injections of the drug for 7 d in
Gad2VTA:Leu9Ser and control animals. Mice were challenged
with 0.09 mg/kg nicotine delivered subcutaneously, a dose that
activated GABAergic neurons in Gad2VTA:Leu9Ser but had little
effect on neuronal activation in control mice. In control mice,
0.09 mg/kg nicotine did not significantly modulate locomotor
activity compared to saline injection (Fig. 3A). In Gad2VTA:
Leu9Ser mice, one-way ANOVA revealed a significant main ef-
fect of nicotine injections on locomotor activity (F(3,18)  7.86,
p 	 0.01). Post hoc analysis revealed that nicotine significantly
depressed locomotor activity upon first injection compared to
saline (p	 0.01), and tolerance to this hypolocomotor response
Figure 2. Selective activation of VTA GABAergic neurons by nicotine in Gad2 VTA:Leu9Ser mice. A, Summed average number of c-Fos-immunopositive [c-Fos()] neurons in the VTA of control
(n 6/group) andGad2 VTA:Leu9Sermice (n 7/group) after challengewith saline or 0.09mg/kg nicotine.B, Representative photomicrographs illustrating c-Fos expression (red) in VTA sections
taken from control (top) or Gad2 VTA:Leu9Ser mice (bottom) mice after 0.09 mg/kg nicotine challenge. Neurons exhibiting TH immunoreactivity are labeled in blue (left), whereas YFP expression
is labeled in yellow (right). C, Summed average number of TH(), c-Fos() and TH(), c-Fos() neurons in the VTA in control (n 6mice) and Gad2 VTA:Leu9Ser mice (n 7) after challenge
with 0.09 mg/kg nicotine. **p	 0.01 [number of TH(), c-Fos() neurons compared to the number of TH(), c-Fos() neurons in Gad2 VTA:Leu9Ser mice after nicotine challenge]; ***p	
0.001 [number of c-Fos() neurons in Gad2 VTA:Leu9Ser mice after nicotine challenge compared to saline challenge]; ^ p	 0.05 [number of neurons that are TH(), c-Fos() in Gad2 VTA:
Leu9Ser mice after nicotine challenge compared to the number of neurons that are TH(), c-Fos() in control mice after nicotine challenge]; ^^^p	 0.001 [number of c-Fos() neurons in
Gad2 VTA:Leu9Ser mice after nicotine challenge compared to the number of c-Fos() neurons in control mice after nicotine challenge]. Error bars indicate SEM.
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occurred with subsequent injections. Thus, acute activation of
nAChRs in VTA GABAergic neurons induces hypolocomotor
activity, which triggers tolerance after subsequent nicotine
exposures.
Sensitivity to nicotine reward is modulated by activation of
VTA GABAergic4* nicotinic receptors
To test the hypothesis that functional upregulation of VTA
GABAergic neurons modulates nicotine reward, the ability of
nicotine to condition a place preference in
Gad2VTA:Leu9Ser and control mice was
measured using the CPP procedure. Dur-
ing training, mice were challenged with
saline or 0.09 or 0.5 mg/kg nicotine (Fig.
3C,D, Table 1), delivered subcutaneously.
In control animals, nicotine did not con-
dition a significant place preference in re-
sponse to either dose (Fig. 3C), similar to
previous reports delivering subcutaneous
nicotine injections with the CPP proce-
dure in C57BL/6J mice (Hilario et al.,
2012), the background strain of the Gad2-
Cre mice. However, a significant CPP in
response to 0.5mg/kgwas observed in this
strain during withdrawal from 6 weeks
chronic nicotine treatment (Fig. 3C, inset;
significantmaineffectofdrug-pairedcham-
ber, F(1,20)  5.97, p 	 0.05; significant
drug-paired chamber by chronic treatment
interaction, F(1,20)  10.10, p 	 0.01; two-
way ANOVA on difference scores, signifi-
cant increase in difference score in the
nicotine-paired chamber between nicotine-
dependent and nicotine-naive mice, p 	
0.01; Table 1). In Gad2VTA:Leu9Ser mice,
two-way ANOVA of difference scores
(Fig. 3D) indicated a significant main ef-
fect of drug (F(1,26)  18.64, p 	 0.001)
but not training chamber (F(2,46) 
0.6807, p  0.05), and a significant drug
by training chamber interaction (F(2,46)
7.086, p	 0.01). Post hoc analysis revealed
a significant difference between difference
scores in the nicotine-paired chamber at
the dose of 0.09mg/kg, but not 0.5mg/kg,
nicotine in Gad2VTA:Leu9Ser mice com-
pared to saline (Fig. 3D). Repeated mea-
sures two-way ANOVA of time spent in
the drug and saline-paired chamber be-
fore and after training with 0.09 mg/kg
nicotine (Table 1) did not indicate signif-
icantmain effects of training or time spent
in either chamber, but did reveal a signif-
icant training by chamber interaction
(F(1,8) 25.48, p	 0.001). A post hoc test
indicated a significant increase in time
spent in the nicotine-paired chamber after
training compared to before training. Fi-
nally, two-way ANOVA of time spent in
the drug-paired chamber before and after
training in Gad2VTA:Leu9Ser mice that
received 0.09 mg/kg nicotine during
training compared to mice that received
saline in the drug-paired chamber (Table 1) indicated a signifi-
cantmain effect of drug (F(1,15) 10.32, p	 0.01) and time spent
in the drug-paired chamber (F(1,15)  7.97, p 	 0.05), and a
significant interaction (F(1,15) 13.19, p	 0.01). Post hoc analy-
sis indicated a significant increase in time spent in the drug-
paired chamber after training with 0.09 mg/kg nicotine
compared to saline. Interestingly, after chronic nicotine expo-
sure, Gad2VTA:Leu9Ser mice did develop a modest CPP to 0.5
mg/kg nicotine (repeatedmeasures two-wayANOVA; significant
Figure 3. Selective activation of VTA GABAergic neurons by nicotine is sufficient for nicotine-induced hypolocomotion and
reward. A, Summed 15 min total locomotor activity after saline injection or daily injection of 0.09 mg/kg nicotine in control mice
(n 7). B, Summed 15 min total locomotor activity after saline injection or daily injection of 0.09 mg/kg nicotine in Gad2 VTA:
Leu9Sermice (n 7). ** p	 0.01, compared to saline challenge. C,D, Difference scores indicate the time spent in the nicotine-
or saline-paired chamber after trainingminus the time spent in thenicotine- or saline-paired chamberbefore training in control (C)
or Gad2 VTA:Leu9Ser mice (D) in response to 0 mg/kg (saline; n 10 and 8, respectively), 0.09 mg/kg (n 9/group), and 0.5
mg/kg nicotine (n 8/group). C, Inset, Difference scores in the CPP assay in response to 0.5 mg/kg nicotine from WT mice
previously exposed to 6 weeks of nicotine or vehicle (n 11/group). ***p	 0.001 (nicotine-paired chamber compared to
saline-paired chamber); ^p 	 0.05 (nicotine-paired chamber in dependent mice compared to nicotine-paired chamber in
nicotine-naive mice); ^^p	 0.01 (nicotine-paired chamber compared to saline in the drug-paired chamber); two-way ANOVA,
Bonferroni’s post hoc test. Error bars indicate SEM.
Figure 4. nAChR antagonists do not condition a place preference in Gad2 VTA:Leu9Ser mice. A, Difference scores in the CPP
assay in response to 1.0mg/kgmecamylamine in control and Gad2 VTA:Leu9Ser mice (n 10/group). B, Difference scores in the
CPP assay in response to 0.5 or 2.0 mg/kg DHE in control mice (n 7/group) and Gad2 VTA:Leu9Ser mice (n 8 and 6,
respectively). Error bars indicate SEM.
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training by chamber interaction, F(1,9) 27.61, p	 0.001; signif-
icant increase in time spent in the nicotine-paired chamber after
training, p	 0.05; Table 1).
Whereas a low dose of nicotine may elicit a CPP in Gad2VTA:
Leu9Ser mice by activating GABAergic neurons, it is also possi-
ble that nicotine may be desensitizing Leu9Ser 4-YFP nAChRs
in VTA GABAergic interneurons, reducing endogenous ACh ac-
tivation of the mutant nAChRs (i.e., blocking GABAergic in-
terneuron activity) and thereby disinhibitingDAergic neurons to
promote reward (Mansvelder et al., 2002). We hypothesized that
if this were occurring, then an nAChR antagonist would elicit a
similar effect by blocking endogenous activity through the
Leu9Ser 4-YFP nAChRs. Thus, we measured the ability of the
noncompetitive nAChR antagonist mecamylamine to condition
a place preference in Gad2VTA:Leu9Ser and control, nicotine-
naive animals. In both groups, 1.0mg/kgmecamylamine failed to
significantly condition a place preference (Fig. 4A). In an addi-
tional group of Gad2VTA:Leu9Ser and control nicotine-naive
animals, we tested whether DHE, a selective 42 competitive
antagonist, would be sufficient to disinhibitDAergic neurons and
condition a place preference. Training with 0.5 or 2.0 mg/kg
DHE, subcutaneously, in control and Gad2VTA:Leu9Ser mice
failed to condition a place preference (Fig. 4B). These data indi-
cate that selective activation of 4* nAChRs in GABAergic neu-
rons is sufficient for nicotine reward.
Gad2VTA:Leu9Ser mice4* nAChRs are expressed in VTA
GABAergic neurons that project to the lateral habenula
To gain insight into the neuronal subpopulation(s) of VTA
GABAergic neurons that may express the Leu9Ser 4-YFP sub-
unit and elicit nicotine-induced reward inGad2VTA:Leu9Ser an-
imals, we immunolabeled C57BL/6J midbrain slices with
potential GABAergic neuronal markers calretinin, calbindin, so-
matostatin, and parvalbumin (Fig. 5A). Interestingly, we did not
detect somatostatin nor parvalbumin expression in the area of
the VTA that was targeted with our virus expression system (that
is, the posterior VTA), although somatostatin expression was
observed in the rostral interpeduncular nucleus as described pre-
viously (Zhao-Shea et al., 2013). Both calretinin- and calbindin-
immunopositive cells were detected (Fig. 5A). However, analysis
of YFP signal in Gad2VTA:Leu9Ser mice revealed that calretinin-
and calbindin-immunopositive neurons did not express YFP
(Fig. 5A, insets), consistent with previous reports that the major-
ity of calretinin- and calbindin-expressing VTA neurons are ac-
tually DAergic (Olson and Nestler, 2007). We next analyzed YFP
signal in knownVTA efferent brain regions of Gad2VTA:Leu9Ser
mice including the NAc, prefrontal cortex (PFC), and lateral ha-
benula (LHb), for YFP fluorescence (Fig. 5B,C). Interestingly,
YFP signal was not detected in the PFC or NAc. However, fluo-
rescence was observed in the LHb.
Discussion
We expressed Leu9Ser 4-YFP nAChR subunits in VTA
GABAergic neurons in an effort to understand how functional
upregulation of4* nAChRs in this neuronal subpopulationmay
contribute to behaviors associated with nicotine dependence.
Chronic nicotine upregulates 4* nAChRs selectively in GABAe-
rgic neurons of the VTA, and this is accompanied by an increase
in functional expression as measured by an increase in nicotine
activation of these neurons (Nashmi et al., 2007). It is important
to note that if chronic nicotinemerely upregulated the4 nAChR
subunit and not the2 subunit, then this would result in a change
in 42 nAChR stoichiometry to the low sensitivity (4)3(2)2
subtype (Eaton et al., 2014). However, a functional increase in
activation is observed in chronic nicotine-treated animals, sug-
gesting that upregulation of both 4 and 2 subunits occurs
(Srinivasan et al., 2011), leading to the observed increase in
nAChR function in GABAergic VTA neurons. To mimic this
phenomenon, we chose to express gain-of-function 4 nAChR
subunits in GABAergic VTA neurons instead of wild-type (WT)
subunits, whichwould have likely changed the42 nAChR stoi-
chiometry to the low sensitivity (4)3(2)2 subtype resulting in a
loss-of-function phenotype.
In Gad2VTA:Leu9Ser mice, a low dose of 0.09 mg/kg nicotine
was sufficient to activate GABAergic neurons. This same dose
failed to significantly activate neurons in control animals. Inter-
estingly, there were few DAergic neurons activated in both
control and Gad2VTA:Leu9Ser mice after low-dose nicotine
challenge. Importantly, nicotine was delivered subcutaneously in
these experiments, whereas this same dose has been shown to
Figure 5. GABAergic neurons mediating reward in Gad2 VTA:Leu9Ser mice include neurons that project to the lateral habenula. A, Representative photomicrographs illustrating calretinin (top
left), calbindin (bottom left), parvalbumin (top right), and somatostatin (bottom right) immunolabeling (red) in C57BL/6J midbrain sections. Insets depict distinct localization of calretinin or
calbindin (red) compared to YFP expression (yellow) in Gad2 VTA:Leu9Ser mice. B, Depiction of a coronal section from a Gad2 VTA:Leu9Ser mouse used for analysis of GABAergic projections. The
photomicrograph illustrates YFP signal in the VTA. C, Representative photomicrographs from cortical (top), striatal (middle), and epithalamic (bottom) sections from the Gad2 VTA:Leu9Ser mouse
in B. IPN, Interpeduncular nucleus; ml, mammillary nucleus; aca, anterior commissure; MHb, medial habenula.
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elicit reward in mice when delivered intraperitoneally, highlighting
that routes of nicotine administration yield differences in bioavail-
ability of the drug (Brunzell et al., 2009; Alcantara et al., 2014).
Acute nicotine activation of VTA GABAergic neurons
induces hypolocomotion
We assessed how functional upregulation of VTA GABAergic
neurons may contribute to nicotine tolerance and reward. Acute
nicotine induces hypolocomotion in rodents, which is alleviated
with multiple nicotine exposures, providing a behavioral mea-
sure of tolerance (Tapper et al., 2007). Typically, locomotor sup-
pression has been observed in C57BL/6mice given a dose of0.5
mg/kg nicotine in a novel environment or open field (Salas et al.,
2004). A single injection of 0.09 mg/kg nicotine in a novel cage
was sufficient to decrease locomotor activity in Gad2VTA:
Leu9Ser mice, but had little effect on locomotor activity in con-
trol mice. Interestingly, Gad2VTA:Leu9Ser mice developed a
tolerance to this effect with daily low-dose nicotine injections,
indicating that acute activation ofVTAGABAergic neurons induces
hypolocomotion, with subsequent exposures eliciting tolerance to
this effect. The mechanism underlying nicotine-induced hypoloco-
motor activity is unknown.Our data indicate that activation ofVTA
GABAergic neuronsmay cause the initial nicotine-induceddecrease
in locomotor activity perhaps by inhibitingDArelease into the stria-
tum. However, additional experiments will be needed to determine
whether the tolerance to this hypolocomotion involves4*nAChRs
in GABAergic neurons or, alternatively, triggers a non-nAChR
mechanism that opposes hypolocomotion.
Selective activation of VTA GABAergic neurons by nicotine is
sufficient for reward
Previous studies using optogenetic stimulation have shown that
activation of VTA GABAergic neurons can lead to disruption of
reward and induce aversion (Tan et al., 2012; van Zessen et al.,
2012). Surprisingly, selective activation of VTA GABAergic neu-
rons in Gad2VTA:Leu9Sermice using a low dose of nicotine con-
ditioned a robust place preference in these animals, suggesting
that nicotine activation of these neurons may be sufficient for
reward. Conversely, a more typical “rewarding” dose of 0.5
mg/kg subcutaneous nicotine (Hilario et al., 2012; Smith et al.,
2012) failed to elicit a place preference in Gad2VTA:Leu9Ser
mice, consistent with a shift in the inverted-U-shaped dose–re-
sponse curve often seen with nicotine reward and reinforcement
(Picciotto, 2003). In control mice, nicotine failed to condition a
place preference at any of the doses tested.While stress could be a
contributing factor to lack of CPP in control animals, this is
rendered unlikely because mice were habituated to handling be-
fore the beginning of the CPP assay. Our results are similar to
those of Hilario et al. (2012), who demonstrated that withdrawal
from chronic nicotine exposure was necessary for the expression
of nicotine reward and that this is correlated with nAChR up-
regulation. Verifying these data, we confirmed that control mice
withdrawn from chronic nicotine also exhibit a place preference
with 0.5 mg/kg nicotine compared to nicotine-naive mice. Based
on data indicating that (1) increased sensitivity to nicotine re-
ward occurs after chronic nicotine exposure and withdrawal, (2)
sensitivity to nicotine reward correlates with nAChR upregula-
tion (Hilario et al., 2012), (3) upregulation of4* nAChRs occurs
selectively in VTAGABAergic neurons (Nashmi et al., 2007), and
(4) selective activation of functionally upregulated 4* nAChRs
in VTA GABAergic neurons elicits reward, we suggest that up-
regulation of 4* nAChRs specifically in VTA GABAergic neu-
rons increases sensitivity to nicotine reward.
Howmight activation ofGABAergic neurons by nicotine elicit
reward? One possibility is that nicotine desensitizes GABAergic
nAChRs, reducing GABAergic neuron activity and disinhibiting
DAergic neurons (Mansvelder et al., 2002). Our data indicate
that, at least using our expression system, this possibility is un-
likely because (1) we did not observe increased activation of
DAergic neurons (as measured by c-Fos induction) after low-
dose nicotine challenge in Gad2VTA:Leu9Ser neurons, and (2)
mecamylamine and DHE failed to elicit reward in Gad2VTA:
Leu9Ser mice. One caveat to these results is that disinhibition of
DAergic neurons by nAChR desensitization in GABAergic neu-
rons would require that Leu9Ser 4-YFP nAChRs are predom-
inantly expressed in GABAergic interneurons. In analyzing VTA
neuron subpopulations in the injection area of Gad2VTA:
Leu9Ser mice, which was focused on the posterior VTA, we
failed to detect parvalbumin- or somatostatin-immunopositive
neurons, whereas calbindin and calretinin neurons were de-
tected, but did not colocalize with Leu9Ser 4-YFP expression,
consistent with previous studies indicating that these two popu-
lations of neurons are largely DAergic in the VTA (Gerfen et al.,
1987; Olson and Nestler, 2007). A more recent study indicated
that activation of GABAergic neurons via 2* nAChRs is re-
quired for DAergic neuron burst activity and nicotine self-
administration (Tolu et al., 2012). Thus, nicotine activation of
GABAergic neurons in Gad2VTA:Leu9Ser mice could lead to in-
creased DAergic neuron bursting and reward. However, as indi-
cated above, increased activation of DAergic neurons, at least
with acute nicotine injections, was not observed in these animals.
A third and more likely possibility is that a portion of VTA
GABAergic neurons expressing Leu9Ser 4-YFP nAChRs proj-
ect to brain regions that, when inhibited, promote reward behav-
ior. Indeed, upon analysis of known VTA projection regions, we
found Leu9Ser 4-YFP expression in the LHb. GABAergic neu-
rons make up 35% of VTA neurons, and although little is
known about their function within the VTA (Nair-Roberts et al.,
2008), previous studies indicate that a portion of VTA GABAergic
neurons innervate the LHb and, when activated, elicit reward (Sta-
matakis et al., 2013; Lammel et al., 2015). This is accomplished by
inhibiting LHb glutamatergic inputs to the rostromedial tegmental
nucleus (RMTg), which, in turn, disinhibits VTA DAergic neurons
to promote reward (Hong et al., 2011; Lecca et al., 2011). Thus, one
mechanism by which nicotine activation of VTA GABAergic neu-
rons could elicit nicotine reward is through inhibiting these LHb
inputs to the RMTg. Future studies should focus on how VTA
GABAergic neuron activation alters the excitability of these down-
streambrain regions in the context of nicotine-induced reward.Our
data suggest that activationof functionally upregulated4*nAChRs
inVTAGABAergic neurons confers increased sensitivity to nicotine
reward. These data indicate that nAChR subtypes specifically ex-
pressed in VTAGABAergic neuronsmay be goodmolecular targets
for therapeutics to aide in smoking cessation.
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